Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
Rune Viig Overgaard, CHRISTIN L. HERTZ, Steen H. Ingwersen, Andrea Navarria, Daniel J. Drucker
Abstract
and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months. Increased body weight is the most important variable associated with reduced semaglutide exposure for both formulations. Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.
Topics & Concepts
SemaglutideMedicineType 2 diabetesNauseaAdverse effectDiabetes mellitusDulaglutideBody weightInternal medicineVomitingPharmacodynamicsOral administrationPharmacologyLiraglutideEndocrinologyPharmacokineticsDiabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research